Otsuka Bolsters Oncology Portfolio With Acquisition Of PDL’s Busulfex
This article was originally published in The Pink Sheet Daily
Executive Summary
Otsuka acquires first-in-class oncology product with over $29 million in sales for year ended Sept. 30.
You may also be interested in...
PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan
In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.
PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan
In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.
PDL Now Says It Will Consider Sale Of Entire Company
CEO McDade formally steps down, while former board chairman Gage becomes interim CEO.